Segmentation by type distinguishes the molecular origin and production methodology of natural SOD, each influencing cost structure and market adoption. Plant‑derived SOD—extracted from sources such as wheat germ, barley, and soy—captures the largest share, driven by consumer perception of botanical purity and established supply chains. Microbial SOD, obtained from fermentation of Bacillus, Lactobacillus, or yeast strains, offers higher specific activity and scalability, positioning it for pharmaceutical and high‑dose nutraceutical products. Recombinant SOD, produced through genetically engineered E. coli or Pichia platforms, delivers consistent purity and enables targeted protein engineering, thereby attracting premium therapeutic applications despite higher manufacturing expenses. A nascent hybrid formulation category combines natural SOD with stabilizing carriers (e.g., liposomes, cyclodextrins) to improve bioavailability, gradually expanding within both cosmetics and nutraceuticals. The relative contribution of each type aligns with application demand: plant‑derived SOD dominates the cosmetics market, microbial SOD underpins pharmaceutical formulations, and recombinant SOD supports high‑value therapeutic pipelines.